Alectinib (Alecensaro)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses alectinib (Alecensaro), 150 mg capsules, oral. Indication: For adjuvant treatment following tumour resection for patients with stage IB (tumour ≥ 4 cm) to IIIAa ALK-positive non–small cell lung cancer.